April W. Armstrong - Concepedia

Author

April W. Armstrong

Also Known As

A Armstrong, A. Armstrong, A. W. ARMSTRONG, A. W. Armstrong, A.-W. Armstrong, A.W. Armstrong, APRIL W. ARMSTRONG, April Armstrong, April W Armstrong, April W. Armstrong

852

Publications

26.5K

Citations

H-Index

155

Concepts

All Affiliations

University of Southern California University of California, Davis Icahn School of Medicine at Mount Sinai University of Pennsylvania Oregon Medical Research Center

About

April W. Armstrong is an author at University of Southern California specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Education	4	4	263
2	Engineering	3	3	161
3	Arts	2	2	76
4	Health Sciences	2	2	127
5	Business	1	1	23

April W. Armstrong

187

Publications

13.4K

Citations

H-Index

Page 1

	Year	Citations
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis Laura C. Coates, Arthur Kavanaugh, Philip J. Mease, Arthritis & Rheumatology	2016	899
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl, Bruce Strober, Alan Menter, New England Journal of Medicine	2015	790
Psoriasis prevalence among adults in the United States Tara Rachakonda, Clayton W. Schupp, April W. Armstrong Journal of the American Academy of Dermatology Psoriasis PrevalenceMedicineClinical DermatologyDermatologyPsoriatic Arthritis	2014	775
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Kristian Reich, April W. Armstrong, Peter Foley, Journal of the American Academy of Dermatology	2017	712
Psoriasis Prevalence in Adults in the United States April W. Armstrong, Manan D. Mehta, Clayton W. Schupp, JAMA Dermatology	2021	432
Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States April W. Armstrong, Andrew D. Robertson, Julie Wu, JAMA Dermatology	2013	387
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Kristian Reich, April W. Armstrong, Richard G. Langley, The Lancet Systemic TreatmentGuselkumab Versus SecukinumabClinical DermatologyPharmacotherapyDermatology	2019	362
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield, JAMA Dermatology	2020	329
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial April W. Armstrong, Melinda Gooderham, Richard B. Warren, Journal of the American Academy of Dermatology	2022	316
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies Alan Menter, Joel M. Gelfand, Cody Connor, Journal of the American Academy of Dermatology Systemic Nonbiologic TherapiesSystemic TreatmentClinical DermatologyDermatologyScleroderma	2020	314

Page 1